W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

28 July, 2022

Recommendation of the President – Opdivo (nivolumab) in combination with Yervoy (ipilimumab)

26 July, 2022

Opinion of the Transparency Council – health policy programme on therapeutic rehabilitation (town of Żyrardów)

26 July, 2022

Opinion of the Transparency Council – health policy programme on breast cancer prevention (town of Sieradz)

26 July, 2022

Opinion of the Transparency Council – changes to the drug programme B.61

26 July, 2022

Opinion of the Transparency Council – active substance ipratropii bromidum

26 July, 2022

Opinion of the Transparency Council – active substances fenoteroli hydrobromidum + ipratropii bromidum

26 July, 2022

Opinion of the Transparency Council – active substance prednisone

26 July, 2022

Opinion of the Transparency Council – active substances amiloridum + hydrochlorothiazidum

26 July, 2022

Opinion of the Transparency Council – health policy programme on medical rehabilitation (Municipality of Mielno)

26 July, 2022

Opinion of the Transparency Council – health policy programme on detection of vision defects (Municipality of Chociwel)

26 July, 2022

Opinion of the Transparency Council – health policy programme on detection of vision defects (town of Będzin)

26 July, 2022

Position of the Transparency Council – Rezurock (belumosudil)

26 July, 2022

Position of the Transparency Council – Yervoy (ipilimumab)

26 July, 2022

Position of the Transparency Council – Opdivo (nivolumab)

26 July, 2022

Opinion of the Transparency Council – combining drug programmes B.29 and B.46

26 July, 2022

Position of the Transparency Council – non gamma 2 capsule amalgam

21 July, 2022

The Meeting of the Transparency Council No. 29/2022 of 25.07.2022

20 July, 2022

Communication on the meeting of the Tariff Council on 14.07.2022

19 July, 2022

The Meeting of the Tariffs Council No. 18/2022 of 28.07.2022

18 July, 2022

Opinion of the President – ,,Prevention of overweight and obesity in children in class III of primary schools in the Municipality of Kołobrzeg for the period 2022 – 2024”

15 July, 2022

The Meeting of the Tariffs Council No. 17/2022 of 21.06.2022

13 July, 2022

Announcement of the President – recommendation on the change of the method or level of healthcare service financing

13 July, 2022

Opinion of the Transparency Council – leflunomidum

13 July, 2022

Position of the Transparency Council – Livmarli (maralixibat)

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy